The Moderate Alcohol and Cardiovascular Health Trial (MACH15)

The Moderate Alcohol and Cardiovascular Health Trial (MACH15) was a longitudinal, international clinical trial to determine the effects of moderate alcohol use on cardiovascular disease and diabetes. This trial aimed to look at the health effects of a single daily serving of alcohol in individuals aged 50 and over who have above average risk for cardiovascular health problems. To do that, trial investigators would have randomly divided 7,800 study participants at 20 sites worldwide into two groups – one group that will drink one serving of alcohol (approximately 15 grams) a day, and another group that will abstain from alcohol. The trial was being conducted by the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Due to the clinical trial’s large size and scale, NIAAA could not fund the study on its own. In early 2015, the NIAAA called upon the FNIH to raise funds from the private sector to support the trial and the FNIH began to secure funding that summer. 

Updates:

12/13/18: FNIH Statement on the Moderate Alcohol and Cardiovascular Health Trial Follow-Up Report

As of 9/6/18, unused project donations have been returned to the funders.

6/15/18: FNIH Statement on the Moderate Alcohol and Cardiovascular Health Trial Working Group Report and NIH Statement: NIH to end funding for Moderate Alcohol and Cardiovascular Health trial. 

Goals

The two primary study objectives were to determine the effects of one serving of alcohol (approximately 15 grams) daily, compared to no alcohol intake, on

  1. the rate of new cases of cardiovascular disease and,
  2. the rate of new cases of diabetes among participants free of diabetes at baseline.

Partners

Beth Israel Deaconess Medical Center
Center for Bioethics and Research, Ibadan, Nigeria
Harvard School of Public Health
Johns Hopkins ProHealth Clinical Research Center
Julius Center, Zeist, Netherlands
National Institute on Aging (NIA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute of Neurological Disorders and Stroke (NINDS)
Wake Forest University Health Sciences

Funders

For this program, funders had no role in the study beyond providing donations.

Anheuser-Busch InBev
Carlsberg Breweries A/S
Diageo plc
Heineken 
Pernod Ricard USA LLC.

Contact

Development@fnih.org